About ITUS

Investing in growth in the public markets

Research Center

Study our investing style and process at length

Owner's Manual

Owner's Manual

We are a fiduciary of your capital. Your understanding of what we do and how we will approach it is a critical element in enabling us to attain our goal. The Owners Manual helps achieve this....

Learn more

The Indian pharmaceutical sector, renowned for its role as a leading supplier of generic drugs worldwide, has faced heightened scrutiny due to recent tariff-related developments. For portfolios with significant exposure to the industry, it is crucial to separate noise from substance when evaluating its prospects. While the announcement of potential U.S. tariffs on Indian imports has fuelled short-term volatility, the fundamentals of Indian pharma remain robust. Nearly half of all generic drugs consumed in the U.S. originate from India, contributing to billions in annual healthcare savings. This underscores the sector’s indispensable role in addressing global health needs.

Resilience of India's Pharma Sector Amid Tariff Concerns

Concerns about tariffs triggering drastic shifts in supply chains are exaggerated. Indian companies operate efficiently on thin margins, leveraging cost-effective manufacturing processes. Even if tariffs marginally increase prices, it is unlikely to compromise their competitive edge entirely. Moreover, relocating production to the U.S. for generics is economically unfeasible, mitigating risks of abrupt operational changes. It is the media spotlight on trade tensions, rather than inherent weaknesses, that has sparked panic in the market. Historically, such episodes have proven to be transient, with recovery driven by industry resilience and demand consistency.

For portfolios with a 20% overweight position in the pharma sector like ITUS, this phase presents a buying opportunity. Investors need to focus on fundamentals and ignore short-term market noise and keep investing in these opportunities that market provides to us.

Stay invested! 

We have written about how investing in volatile market can benefit your overall returns of the portfolio.  You can read about it in the below link –  Series 96 – Market Cycles and Investing Strategy – ITUS Capital 

Keep following us for more contents like these. As always, we keep re-emphasising our SIP mode of investment. You can connect with your relationship manage to know more about our SIP Program.

These weekly episodes are now available in our website for your quick read and you may access the same in the below link.

Weekly Enlightenment Archives – ITUS Capital